There are 2789 resources available
532P - Phase Ib study evaluating BI 836880 (VEGF/Ang2 nanobody) in combination with ezabenlimab (BI 754091; anti-PD-1 antibody) in patients with solid tumours
Presenter: Nicolas Girard
Session: ePoster Display
1150TiP - A phase II, open-label, multi-dose study of [89Zr]Zr-Df-IAB22M2C (CD8 cell PET tracer) PET/CT in patients with selected advanced or metastatic solid malignancies scheduled to receive standard of care immunotherapy, as single agent or in combination
Presenter: Kim Margolin
Session: ePoster Display
1152P - Real-world outcomes in resected stage IB-IIIA EGFR mutated NSCLC in Canada: Analysis from the POTENT study
Presenter: M. Kuruvilla
Session: ePoster Display
1153P - Classification of multifocal lung adenocarcinomas subtypes using next-generation sequencing in pN0M0 lung adenocarcinomas
Presenter: Xin Zhang
Session: ePoster Display
1154P - Circulating tumor DNA analysis integrating tumor clonality detects minimal residual disease in resectable non-small cell lung cancer
Presenter: Rong Yin
Session: ePoster Display
1155P - Univariable and multivariable two-sample Mendelian randomization investigating the effects of leisure sedentary behavior on the risk of lung cancer
Presenter: Haoxin Peng
Session: ePoster Display
1156P - Exosomal lncRNA HOTTIP assessment for non-small cell lung cancer surveillance after curative-intent surgery
Presenter: Han Bing
Session: ePoster Display
1157P - Diagnostic therapeutic pathway (DTP) of early stage non-small cell lung cancer (eNSCLC): A real-world focus on EGFR status detection in resected patients (pts)
Presenter: Giulia Pasello
Session: ePoster Display
1158P - Real-world adjuvant treatment patterns and survival outcomes among early NSCLC US patients
Presenter: Jay Lee
Session: ePoster Display